About
About Collegium Pharmaceutical, Inc
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. Collegium Pharmaceutical, Inc. was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. The company was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Visit company website
5 years, 5 months ago
Collegium Pharmaceutical, Inc is currently in a long term uptrend where the price is trading 5.2% above its 200 day moving average.
From a valuation standpoint, the stock is 99.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.7.
Collegium Pharmaceutical, Inc's total revenue rose by 2.8% to $76M since the same quarter in the previous year.
Its net income has increased by 416.1% to $7M since the same quarter in the previous year.
Finally, its free cash flow grew by 42.9% to $21M since the same quarter in the previous year.
Based on the above factors, Collegium Pharmaceutical, Inc gets an overall score of 5/5.